Inactive Instrument

ALPHANCO VEN

Equities

AVC.P

CA02079V1031

Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2020

October 16, 2020 at 04:06 pm EDT

Alphanco Venture Corp. announced earnings results for the full year ended July 31, 2020. For the full year, the company announced net loss was CAD 10,556 compared to CAD 98,044 a year ago. Basic eps - continuing operations was CAD 0 compared to basic loss per share from continuing operations of CAD 0.03 a year ago.

Latest news about ALPHANCO VEN

Alphanco Venture Corp. has Changed its Name to Marvel Biosciences Corp	21-07-08	CI
Marvel Biosciences Corp. Appoints J. Roderick Matheson as Chief Executive Officer	21-07-08	CI
Marvel Biosciences Corp. Appoints Preston J. Maddin as Chief Financial Officer	21-07-08	CI
Marvel Biosciences Corp. Announces Management Appointments	21-07-08	CI
Marvel Biotechnology Inc. completed the acquisition of Alphanco Venture Corp. (TSXV:AVC.P) for CAD 3.8 million in a reverse merger transaction.	21-06-13	CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2021	21-06-10	CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2021	21-03-22	CI
Marvel Biotechnology Inc. entered into a binding letter agreement to acquire Alphanco Venture Corp. (TSXV:AVC.P) in a reverse merger transaction.	20-11-02	CI
Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2020	20-10-16	CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2020	20-05-12	CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2020	20-03-08	CI
Alphanco Venture Corp. Reports Earnings Results for the First Quarter Ended October 31, 2019	19-12-17	CI
Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2019	19-11-07	CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2019	19-06-04	CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2019	19-03-25	CI
Alphanco Venture Corp. has completed an IPO in the amount of CAD 0.4 million.	19-02-28	CI
Alphanco Venture Corp. has filed an IPO in the amount of CAD 0.4 million.	18-12-20	CI
Alphanco Venture Intends To Seek Acquisitions	18-12-20	CI

Chart ALPHANCO VEN

Duration

Period

More charts

Company Profile

Marvel Biosciences Corp, formerly Alphanco Venture Corp, is a Canada-based life sciences company. The Company is focused on discovery and the development of pharmaceutical products for the treatment of neurologically associated diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder ADHD, and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. The Company also intends to advance compound 1b (MB-204) into Phase 1 clinical trials for neurological diseases.

Sector

More about the company